<DOC>
	<DOCNO>NCT00365781</DOCNO>
	<brief_summary>10 healthy volunteer enrol receive two subcutaneous injection ISIS 113715 abdomen Study Day 1 . Each subject receive two injection within 5-minute period . On Study Days 2 8 , subject 's injection site assess dermatologic effect . The Isis Project Physician ( ) observe injection site Study Day 2 may also observe Study Day 8 . Routine clinical chemistry , hematology , urinalysis test perform Study Day 1 Day 8 . Subjects contact telephone Study Day 30 monitor occurrence new serious adverse event ( SAEs ) . Thereafter , subject discharge study .</brief_summary>
	<brief_title>Examination Dermatologic Effects From Subcutaneous Injections ISIS 113715</brief_title>
	<detailed_description>Following two-week period subject screening , 10 eligible subject dose subcutaneously ISIS 113715 single calendar date ( Study Day 1 ) . Each subject receive two subcutaneous injection give within 5-minute period . The first injection 200 mg ISIS 113715 give 1.0 mL inject 7.5 cm leave umbilicus . The second injection 200 mg ISIS 113715 give 2.0 mL inject 7.5 cm right umbilicus . Both injection deliver use 3.0-mL syrinx outfit 30-gauge , 0.5-inch needle . To minimize variability , injection perform single individual , Investigator designee , employ uniform technique injection . Dermatologic responses injection site assess 1 7 day injection ( Study Days 2 8 , respectively ) . Effects evaluate completion Injection Site Assessment Questionnaires Investigator record adverse event report subject observed Investigator . The Isis Project Physician ( ) observe injection site Study Day 2 may also observe Study Day 8 . Routine clinical chemistry , hematology , urinalysis test perform Study Days 1 ( prior administration ISIS 113715 ) 8 . Subjects contact telephone Study Day 30 monitor occurrence new serious adverse event . Thereafter , subject discharge study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female : Females post menopausal surgically sterile ; Males surgically sterile , abstinent , utilize acceptable barrier contraceptive method . Must also agree continue abstinence and/or use acceptable barrier contraceptive method least four week injection ISIS 113715 Aged 18 65 year Weight &gt; 50 kg Body mass index &gt; 29 kg/mÂ² Pregnant , breastfeeding , intend become pregnant Positive hepatitis B virus , hepatitis C virus , HIV test History clinical significant abnormality complement coagulation parameter take medication may affect coagulation ( e.g. , heparin , warfarin ) , except aspirin nonsteroidal antiinflammatory agent ( NSAID ) Current history significant skin disorder History alcohol drug abuse History liver renal disease Malignancy ( exception basal squamous cell carcinoma skin adequately treat recurrence &gt; one year ) Liver function test great Upper Limit Normal ( ULN ) Clinically significant currently active disease active infection require antiviral antimicrobial therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Injection Site Reaction</keyword>
	<keyword>Subcutaneous administration</keyword>
	<keyword>Dermatological effect</keyword>
	<keyword>Antisense</keyword>
</DOC>